Skip to content

Intravaginal Treatment of Disturbances of Vaginal Flora Among HIV Infected and Uninfected Women in Malawi

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00140764
Enrollment
Unknown
Registered
2005-09-01
Start date
2003-01-31
Completion date
2005-03-31
Last updated
2011-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Vaginosis, Trichomonas Vaginitis, Urogenital Diseases

Keywords

Genitourinary symptoms

Brief summary

The purpose of this intervention is to find out whether intravaginal treatment with a gel containing an antibiotic (metronidazole), compared to a similar placebo gel (without antibiotic), can reduce the frequency of bacterial vaginosis, a common vaginal infection among African women who are HIV uninfected or HIV infected. The study will also determine the effect of these vaginal gels on genitourinary symptoms.

Detailed description

This is a phase 3, randomized, double masked, two arms study conducted in Malawi, Southeast Africa. The study is conducted among nonpregnant HIV infected or uninfected women of reproductive age. Intermittent mass treatment approaches are followed where women are randomized to antibiotic intravaginal treatment or placebo at enrollment. Women receive assigned product every three months for one year.

Interventions

DRUGMetronidazole gel versus placebo gel

Sponsors

Johns Hopkins Bloomberg School of Public Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years

Inclusion criteria

Nonpregnant HIV-Uninfected HIV-Infected

Exclusion criteria

Pregnant

Design outcomes

Primary

MeasureTime frame
Prevalence of bacterial vaginosis
Reported genitourinary symptoms

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026